New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
17:11 EDTEXASExact Sciences' Cologuard shows 'unprecedented' rates of cancer detection
According to the Mayo Clinic, results of a clinical trial of Cologuard show unprecedented rates of precancer and cancer detection by a noninvasive test. The detection rates are similar to those reported for colonoscopy. The results were published in the March 20 issue of the New England Journal of Medicine. Cologuard was co-developed by Mayo Clinic and Exact Sciences. Cologuard, is a noninvasive sDNA test for the early detection of colorectal precancer and cancer. The clinical trial, called the DeeP-C study, included 10,000 patients and was designed to determine how well Cologuard detects precancer and cancer. The study also compared Cologuard to the fecal immunochemical test for occult blood. The study was conducted at 90 medical centers throughout the United States and Canada. According to the Mayo Clinic's website, the release is under embargo until March 19, at 5:00 pm ET, though it was visible on the "News Resources" section of the site. As of 5:00 pm ET on March 18, the post appeared to have been removed. Shares of Exact, which gained $1.29, or 9.82%, to close at $14.42 during today's session, are up an additional $1.09, or 7.56%, to $15.51 in after hours trade. Reference Link
News For EXAS From The Last 14 Days
Check below for free stories on EXAS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 19, 2014
14:56 EDTEXASExact Sciences volatility elevated
Exact Sciences October call option implied volatility is at 88, November is at 78, January is at 71; compared to its 26-week average of 66 according to Track Data, suggesting large near term price movement.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use